WorldPing
WorldPingFortune
Sam Altman says OpenAI’s IPO window has been pushed to 2027—but markets aren’t the culprit
Altman called right now an ‘ill-advised moment to go public.’…
Brief by WorldPing · Original reporting by Fortune
CNBC World
OpenAI boss Sam Altman spells out how and why the AI industry wants to slow down: 'We could lose control'
OpenAI's chief has made comments detailing how AI safety frameworks and a slowdown could work, as the industry unites behind concerns.
This is a short WorldPing brief. The full report was published by CNBC World.
Read the full report at CNBC WorldMore coverage: all world news on WorldPing.
Related news
WorldPing
WorldPingTimes of India
Cochin shipyard goes global: Why Indian Navy could be the biggest winner
India and UAE are deepening maritime cooperation with a new joint venture. This partnership will expand the International Ship Repair Facility at Kochi. The venture aims to transform Kochi into a major ship repair hub.
Brief by WorldPing · Original reporting by Times of India
CNBC World
WorldPingCNBC World
Wealthy Chinese, tech talent confront tighter borders as Beijing widens exit controls
China's new border-control regulations are designed to keep two of its most valuable assets from leaving the country: money and talent.
Brief by WorldPing · Original reporting by CNBC World
WorldPingNPR Top
This bill could reshape crypto in America -- and it's sparking a major battle
The legislation would establish rules of the road for the crypto sector for the first time — but opponents are up in arms, and the bill faces an uncertain prospect in the Senate.
Brief by WorldPing · Original reporting by NPR Top
CNBC World
WorldPingCNBC World
CNBC's The China Connection newsletter: Tech controls expand to employees
As the U.S.-China tech rivalry simmers, Beijing is increasing restrictions on how its companies can deploy their tech talent overseas.
Brief by WorldPing · Original reporting by CNBC World
WorldPingNew Scientist
LSD could be approved for anxiety in the US in 2027
The psychedelic drug LSD eased anxiety in a late-stage trial, paving the way for a probable approval in the US within the next two years…
Brief by WorldPing · Original reporting by New Scientist